𝗡𝗲𝘄 𝗠𝗲𝘁𝗵𝗼𝗱 𝗳𝗼𝗿 𝗦𝗰𝗮𝗹𝗮𝗯𝗹𝗲 𝗣𝗿𝗼𝘁𝗲𝗶𝗻 𝗗𝗲𝘀𝗶𝗴𝗻 𝗘𝘅𝗽𝗮𝗻𝗱𝘀 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗼𝗳 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 An international consortium, including researchers from Technische Universität München (origin of CPTx), Fudan University of Shanghai, Harvard University, and Massachusetts Institute of Technology (MIT), has published in Science Magazine a new method for 𝘀𝗰𝗮𝗹𝗮𝗯𝗹𝗲 𝗽𝗿𝗼𝘁𝗲𝗶𝗻 𝗱𝗲𝘀𝗶𝗴𝗻 called 𝗿𝗲𝗹𝗮𝘅𝗲𝗱 𝘀𝗲𝗾𝘂𝗲𝗻𝗰𝗲 𝗼𝗽𝘁𝗶𝗺𝗶𝘇𝗮𝘁𝗶𝗼𝗻 (𝗥𝗦𝗢): https://lnkd.in/dvXGAPvZ. The study draws on advancements in machine learning for protein structure prediction and design, building on the groundbreaking innovations of 2024’ Nobel Prize laureates David Baker, Demis Hassabis, and John Jumper. The work on RSO introduces an efficient way to perform gradient descent-based protein design, allowing for the creation of large and complex proteins, offering potential applications in new vaccine and therapeutic programs. The research was co-led by our founder and CEO Hendrik Dietz, with Sergey Ovchinnikov (MIT) and arrives at a time when protein design is becoming an increasingly used tool in biotechnology, following significant advances in predictive modelling. Grant Boldt, COO of CPTx, explains that this innovative method allows exploring a wider range of functional protein sequences efficiently, accelerating research and delivering breakthrough treatments to patients faster. CPTx sees potential in leveraging RSO to develop composite programmable therapeutics, further expanding its portfolio of biopharmaceutical assets focused on addressing outsized medical needs. The pipeline allows for rapid prototyping of protein backbones, which can be tuned for different applications, such as designing binders, functional scaffolds, or large proteins (currently up to 1,000 amino acids). The technology was validated both computationally (via in silico comparisons and benchmarking) and experimentally (through protein expression and structural analysis). For more information on the study, visit https://lnkd.in/dvXGAPvZ (𝗦𝗰𝗮𝗹𝗮𝗯𝗹𝗲 𝗽𝗿𝗼𝘁𝗲𝗶𝗻 𝗱𝗲𝘀𝗶𝗴𝗻 𝘂𝘀𝗶𝗻𝗴 𝗼𝗽𝘁𝗶𝗺𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗮 𝗿𝗲𝗹𝗮𝘅𝗲𝗱 𝘀𝗲𝗾𝘂𝗲𝗻𝗰𝗲 𝘀𝗽𝗮𝗰𝗲, Science, Oct 25th 2024 - Christopher F., Ali Khoshouei, Lara Fuss, Dominik Schiwietz, Dominik Putz, Lara Weber, Zhixuan Zhao, Motoyuki Hattori, Shihao Feng, Yosta de Stigter, Sergey Ovchinnikov, Hendrik Dietz). CPTx press release: https://lnkd.in/dbN_UAVF
CPTx
Biotechnologieforschung
Planegg, Bavaria 1.359 Follower:innen
Composite Programmable Therapeutics
Info
At CPTx, we develop new treatment paradigms across unmet medical challenges, with an initial focus on infectious diseases. The flexibility and precision of CPTx's platform support multivalent drug development, which is crucial for addressing complex disease states involving multiple binding sites, such as viruses, cancer, and autoimmune diseases.
- Website
-
https://www.cptx.bio
Externer Link zu CPTx
- Branche
- Biotechnologieforschung
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Planegg, Bavaria
- Art
- Privatunternehmen
- Gegründet
- 2021
Produkte
Orte
-
Primär
Semmelweisstraße 1
Planegg, Bavaria 82152, DE
Beschäftigte von CPTx
Updates
-
CPTx hat dies direkt geteilt
We are looking forward to attending the #ESGCT 31st Annual Congress in Rome next week, from October 22-25, 2024. If you’ll be there, feel free to reach out to Annemarie Maier or contact us at info@gxstrands.com to schedule a meeting. We’d love to connect and discuss gxstrands’ ssDNA services in person. #gxstrands is at the forefront of pioneering single-stranded DNA solutions, driving the innovations that are shaping the future of genetic research and medical therapies. #ESGCT #ESGCT2024 #genetherapy #celltherapy #gxstrands
-
We are looking forward to attending the #ESGCT 31st Annual Congress in Rome next week, from October 22-25, 2024. If you’ll be there, feel free to reach out to Annemarie Maier or contact us at info@gxstrands.com to schedule a meeting. We’d love to connect and discuss gxstrands’ ssDNA services in person. #gxstrands is at the forefront of pioneering single-stranded DNA solutions, driving the innovations that are shaping the future of genetic research and medical therapies. #ESGCT #ESGCT2024 #genetherapy #celltherapy #gxstrands
-
On behalf of CPTx and personally, I would like to extend my heartfelt congratulations to you, David Baker, on your incredible achievements that were finally recognized with the Nobel Prize! This well-deserved honor is a testament to your pioneering work in computational protein design, which has revolutionized our understanding of protein structures and opened new frontiers in biotechnology and medicine. In addition, I would also like to recognize and congratulate your fellow laureates, Demis Hassabis and John Jumper from DeepMind, whose innovative contributions around AI-based protein structure prediction have been transformative, supporting basic research and discovery but also helping synthetic biologists and protein designers to make new proteins. Together, your work has inspired the scientific community and has profound implications for the future of healthcare and therapeutics. As a colleague and long time fan, it has been an honor to witness firsthand the passion and brilliance you bring to everything you do, David. Wishing you and your esteemed colleagues continued success and celebration during this extraordinary moment—you have truly made a lasting impact on the world! Hendrik Dietz Institute for Protein Design, University of Washington University of Washington, Institute for Protein Design Xaira Therapeutics Google DeepMind DeepMind Isomorphic Labs
-
An alle deutschsprachigen Interessierten, die mehr darüber erfahren möchten, was wir bei CPTx tun: Unser Co-Founder und CTO Christian Sigl hat sich mit Startup Insider zu einem ausführlichen Gespräch zusammengesetzt. Er teilt spannende Einblicke in unsere Mission, Technologie und zukünftige Pläne. Viel Spaß beim Zuhören!
🤑 29 𝐌𝐢𝐥𝐥𝐢𝐨𝐧𝐞𝐧 𝐔𝐒-𝐃𝐨𝐥𝐥𝐚𝐫 𝐟ü𝐫 𝐕𝐢𝐫𝐞𝐧 𝐁𝐞𝐤ä𝐦𝐩𝐟𝐮𝐧𝐠 🦠 In Zeiten globaler Pandemien wurde deutlich, wie wichtig innovative Technologien im Kampf gegen #Viren sind. Während #Impfstoffe und antivirale #Medikamente oft Jahre in der Entwicklung benötigen, stellt die Wissenschaft immer wieder neue Ansätze vor, die Hoffnung geben. Eine solche Technologie ist die #DNA-Nanotechnologie, die es ermöglicht, winzige programmierbare Strukturen zu entwickeln, die gezielt gegen Viren eingesetzt werden können. In der neuesten Folge von Startup Spotlight spricht Jan Thomas mit Christian Sigl, CTO und Gründer von CPTx, über diese revolutionäre Technologie. DNA-#Nanotechnologie bietet völlig neue Ansätze für antivirale Therapeutika und könnte die Art und Weise, wie wir Krankheiten bekämpfen, drastisch verändern. 📈 CPTx hat 29 Millionen US-Dollar von privaten und öffentlichen Investoren eingeworben und steht vor wichtigen Meilensteinen in der präklinischen Entwicklung. 🎙️ In der Podcast-Folge erfährst du: - Wie funktioniert die DNA-Nanotechnologie? - Wie weit ist die Entwicklung der Technologie? - Welche Marktchancen hat die Technologie? 💡 Diese Folge gibt einen Einblick in die Zukunft der #Medizin. Neugierig? Hör rein und erfahre mehr über die Zukunft der viralen Bekämpfung! Link in den Kommentaren! #StartupInsider #StartupSpotlight #Podcast
-
At CPTx, we are excited to be backed by incredible investors including BlueYard Capital, SPRIND - Bundesagentur für Sprunginnovationen, Andrej Henkler, Marius Nacht, Bayern Kapital and others on our mission to develop new treatment paradigms for infectious diseases and other outsized medical challenges. We are always looking for more of “the crazy ones” to join us. If you're ready to make a difference, check out our open positions over the coming weeks! CPTx secures $29 Million to Advance Breakthrough Antiviral Platform https://lnkd.in/dShNZXYh
-
We’re #hiring! This time we are on the lookout for a talented HR manager to lead our human resources efforts and help us grow. Discover more about this opportunity and apply now. https://lnkd.in/dx9NDwdR
-
CPTx hat dies direkt geteilt
We’re #hiring! Join Our Team as a Research Associate at CPTx. Are you passionate about biotechnology and eager to contribute to groundbreaking research? We're looking for a dedicated Research Associate to join our team. If you have a keen eye for detail, a strong analytical mindset, and a drive to make a real impact in the biotech field, we would like to hear from you!
-
CPTx hat dies direkt geteilt
We are expanding our Team and are excited to share a unique opportunity for a skilled and committed Immunology Scientist to join CPTx.
-
CPTx hat dies direkt geteilt
We are excited to announce a new opportunity to join our team as a Research Associate Biology! In this role, you'll be at the forefront of cutting-edge projects, working closely with our experts to drive innovation and contribute to impactful research. https://lnkd.in/dymZVz-f
Research Associate Biology / Senior Research Associate Biology (m/f/d/) | Jobs at CPTx
cptx.jobs.personio.de
Ähnliche Seiten
Finanzierung
Letzte Runde
Serie nicht bekannt29.000.000,00 $